Eli Lilly Gains 10% on EU Jaypirca Approval, Joins FDA PreCheck Pilot
LLY•Eli Lilly climbed 10% last week to an all-time high after a European committee endorsed Jaypirca for chronic lymphocytic leukemia and Medicare expanded $50/month coverage for its obesity drugs Zepbound and Foundayo. The FDA selected Lilly among seven companies for its new PreCheck pilot to expedite manufacturing facility reviews.
1. European Committee Endorses Jaypirca
The European Committee for Medicinal Products for Human Use issued a positive opinion recommending Jaypirca for chronic lymphocytic leukemia, paving the way for regulatory approval in the EU and expansion of the drug’s addressable market.
2. Expanded Medicare Coverage for Obesity Drugs
Medicare now offers Zepbound and Foundayo at $50 per month, significantly lowering patient costs and potentially boosting adoption and revenue for Lilly’s cardiometabolic franchise.
3. Manufacturing Review Accelerated by FDA PreCheck
The FDA selected Eli Lilly among seven companies for its PreCheck pilot program, aiming to streamline reviews of new U.S. manufacturing facilities and accelerate capacity expansion.
4. Stock Reaction and Outlook
These regulatory and coverage developments drove a 10% stock increase last week to an all-time high, reflecting investor optimism in growth prospects while underscoring the need to monitor pipeline execution and margin impacts.
